Class III β tubulin expression in nonsmall cell lung cancer;β-tubuline de classe III et cancer du poumon non à petites cellules

Revue des Maladies Respiratoires

Volumn 27, Issue 4, 2010, Pages 383-386

  Seve P ^a,b,c   Dumontet, C ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

Author keywords

Biomarker; Epothilone; Nonsmall cell lung cancer; Tubulin binding agent; III tubulin

Indexed keywords

BETA TUBULIN; CISPLATIN; EPOTHILONE DERIVATIVE; NAVELBINE; PACLITAXEL; PROTEIN SUBUNIT; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77951299279     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmr.2010.03.006     Document Type: Short Survey

References (14)

1. Sève P., and Dumontet C. Chemoresistance in nonsmall cell lung cancer. Curr Med Chem Anticancer Agents 5 (2005) 73-88
2. Dumontet C., and Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17 (1999) 1061-1070
3. Sève P., and Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 9 (2008) 168-175
4. Sève P., Isaac S., Tredan O., Souquet P.J., Pacheco Y., Perol M., et al. Expression of class III β-tubulin is predictive of patient outcome in patients with nonsmall cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11 (2005) 5481-5486
5. Sève P., Mackey J., Isaac S., Tredan O., Souquet P.J., Perol M., et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with nonsmall cell lung cancer receiving paclitaxel. Mol Cancer Ther 4 (2005) 2001-2007
6. Sève P., Lai R., Ding K., Winton T., Butts C., Mackey J., et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable nonsmall cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13 (2007) 994-999
7. Sève P., Reiman T., Lai R., Hanson J., Santos C., Johnson L., et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60 (2007) 27-34
8. Sève P., Reiman T., Isaac S., Trillet-Lenoir V., Lafanechere L., Sawyer M., et al. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 28 (2008) 1161-1167
9. Katsetos C.D., Kontogeorgos G., Geddes J.F., Herman M.M., Tsimara-Papastamatiou H., Yu Y., et al. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 124 (2000) 535-544
10. Rosell R., Scagliotti G., Danenberg K.D., Lord R.V., Bepler G., Novello S., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic nonsmall cell lung cancer. Oncogene 22 (2003) 3548-3553
11. Dumontet C., Isaac S., Souquet P.J., Bejui-Thivolet F., Pacheco Y., Peloux N., et al. Expression of class III beta tubulin in nonsmall cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92 (2005) E25-30
12. Azuma K., Sasada T., Kawahara A., Takamori S., Hattori S., Ikeda J., et al. Expression of ERCC1 and class III β-tubulin in nonsmall cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64 (2009) 326-333
13. Azuma K., Sasada T., Kawahara A., Hattori S., Kinoshita T., Takamori S., et al. Expression of ERCC1 and class III B-tubulin in nonsmall cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 64 (2009) 565-573
14. Dumontet C., Jordan M.A., and Lee F.F. Ixabepilone: targeting beta III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8 (2009) 17-25